Tagged with China

Hong Kong Professor Guangjin Pan, Managing Director of the Centre for Regenerative Medicine and Health (CRMH), discusses how the center’s focuses on translating cutting-edge science into clinical and commercial success – driving Hong Kong’s ambition to become a global biotech hub. As Part of the Hong Kong Institute of Science & Innovation…

Hong Kong A long-standing figure in Hong Kong’s haematology landscape, Professor Kenny Lei has played a pivotal role in advancing lymphoma care and cellular therapies over the past three decades. His contributions span the early adoption of autologous peripheral blood stem cell transplantation and active involvement in establishing the city’s first hospital-based…

Hong Kong In recent years, the Hong Kong Institute of Biotechnology (HKIB) has entered a new phase, shifting from the groundwork of facility-building to the clinical delivery of locally manufactured CAR-T therapies. Managing Director Gina Jiang reflects on this transition and shares how early operational lessons are in forming a wider platform…

China As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as the population ages, that number is expected to climb. A new report from Selesta looks at the country’s current standards…

Hong Kong In our field, success is not defined by short-term remission alone, but by long-term disease eradication. Our goal is always a cure, not prolonged management. After decades spent advancing paediatric oncology in Hong Kong, Professor Li Chi Kong has increased his focus toward the frontier of cell and gene therapies, spearheading…

Hong Kong For anyone seeking a place where world-class science and a balanced lifestyle can coexist, Hong Kong offers a uniquely compelling proposition. As China’s pharmaceutical landscape expands into innovative biologics, SPH Biotherapeutics (HK) – an R&D affiliate of Shanghai Pharma – is advancing a dual-targeting CAR-T platform with early clinical results…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US rights of tocilizumab biosimilar from Biogen, GE Healthcare’s acquisition of Japan’s Nihon Medi-Physics, Wuxi Biologics’ disposal of vaccine facility to…

APAC This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to Bayer, AbbVie accusing Genmab of ADC trade secret theft on ADC technology used by ProfoundBio, and Singapore’s A*STAR investing in…

China 2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how and why.   Driven by drugmakers’ growing interest in accessing the world’s second-largest pharmaceutical market, China has recently seen a…

China Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by blacklisting the American gene sequencing giant. But beyond the implications for the company, as the trade conflict continues to rage…

Asia A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean biotech getting a 187 million dollar funding boost, why the Australian regulator has rejected Eisai’s Alzheimer’s drug, the activist fund…

China A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction of US biotech Illumina; Bio X Cell’s new Beijing distribution centre, and the European approval of Shanghai Henlius Biotech’s extensive-stage…